1 Groupe d'analyse, Ltee, Montreal, QC, Canada, 2 Janssen-Cilag, Neuss, Germany, 3 Analysis Group, Inc., Boston, MA, USA OBJECTIVES: To examine the economic impact of generic substitution of the antiepileptic drug (AED) Topiramate in Canada; and convert observed Canadian costs into the settings of France, Germany, Italy and the UK (UK). METHODS: Retrospective health claims from Québec's provincial health plan (RAMQ) between January 2006 and September 2008, and IMS Health data on European AED sales between 1998 and 2008 were used. Patients with epilepsy 780.3, 780.39 ) and 2 topiramate dispensings were selected. Patient-level health care utilization costs in Canada were calculated during mutually-exclusive periods of brand versus generic use of topiramate. Annualized Canadian health care costs were projected in each country (a2007/person-year) using Canadian rates, European prices and service-use ratios. Using market-level sales, topiramate utilization were forecasted for 12 months following expected generic entry (September 2009-September 2010) using autoregressive and panel-data regression models. The impact of generic entry was projected for each country, stratified into its effect on market size, topiramate costs, and other health care costs. RESULTS: A total of 1164 patients (mean age: 39.8 years, 61.7% female) were observed for 2.6 years on average. Projected per-patient health care costs in G4 European countries, excluding Topiramate, would be significantly higher during generic-use periods (adjusted cost differences per person-year: a706 to a815, p 0.001 for all comparisons) compared to brand-use periods. Assuming mandatory generic substitution for all patients, predicted system-wide increases in total adjusted health care costs would range from 3.5% (UK) to 24.4% (France) one year after generic entry. Increases in non-Topiramate health care costs ( 13.7% to 18.1%) would more than offset savings in incremental Topiramate brand costs ( 6.3% to 13.8%) in France, Italy, and the UK. CONCLUSIONS: The generic entry of Topiramate in Europe is projected to be associated with higher health care costs, representing a trade-off between reduced generic drug expenditures and increased health care costs.
PND16 ECONOMIC IMPACT OF GENERIC ENTRY OF TOPIRAMATE IN GERMANY: CONVERSION OF THE CANADIAN EXPERIENCE INTO THE SETTINGS OF GERMANY
Paradis PE 1 , Latremouille-Viau D 1 , Moore Y 1 , Mishagina N 1 , Lafeuille MH 1 , Lefebvre P 1 , Gaudig M 2 , Duh MS 3 1 Groupe d'analyse, Ltee, Montreal, QC, Canada, 2 Janssen-Cilag, Neuss, Germany, 3 Analysis Group, Inc., Boston, MA, USA OBJECTIVES: investigated the impact of generic substitution of the branded antiepileptic drug (AED) Topiramate (Topamax®) on medical service utilization and costs for patients with epilepsy in Germany. METHODS: Retrospective health claims from Québec's provincial health plan (RAMQ) between January 2006 and September 2008 were analyzed. Patients with epilepsy (ICD-9: 345, 780.3 or 780.39) and 2 topiramate (Topamax®) dispensings were selected. Patient-level health care utilization and costs in Canada were calculated during mutually-exclusive periods of brand versus generic use of topiramate. Annualized Canadian health care costs were converted into a German setting (a2007/person-year) by applying purchasing power parities, serviceuse ratios and exchange rates. Using market-level sales, branded and generic topiramate utilization were forecasted for 12 months following expected generic entry (September 2009-September 2010) using autoregressive and panel-data regression models. Non-parametric bootstrap procedure was used to determine statistical significance for the cost measures. Budgetary consequences for sick funds, individual and private payers were assessed. RESULTS: After adjusting for covariates, periods of generic topiramate use were associated with significant increases in pharmacy dispensings (other AEDs: 6%, non-AEDs: 31%, p 0.001), a 17% increase in hospitalizations (p 0.015), and 21% longer lengths of hospital stays (p 0.001). Converted per-patient health care costs excluding topiramate were estimated to be significantly higher for generic relative to brand periods in Germany (adjusted cost difference per person-year [95% CI]: a710 [a149-a1283]; p 0.001). Assuming mandatory generic substitution for all patients, predicted system-wide increase in total adjusted health care costs would be 23.2% one year after generic entry. This impact would be evenly distributed among payers. CONCLUSIONS: Generic entry of topiramate in Germany would represent a trade-off between reduced generic drug expenditures and increased health care costs due to higher AED and non-AED spending, as well as increased hospitalizations and outpatient visits. Increased total cost is expected to outweigh the benefit of reduced drug costs.
PND17 THE COST-EFFECTIVENESS OF DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE PATIENTS
Dams J 1 , Siebert U 2 , Bornschein B 2 , Volkmann J 3 , Deuschl G 3 , Oertel WH 1 , Reese JP 1 , Dodel R 1 1 Philipps-University, Marburg, Germany, 2 UMIT University of Health Sciences, Medical Informatics, and Technology, Hall i. T, Austria, 3 Christian-Albrechts-University, Kiel, Germany OBJECTIVES: In addition to medical treatment, deep brain stimulation (DBS) has become an alternative therapeutical option in advanced Parkinson's disease, especially for motor complications such as dyskinesias or motor fluctuations. High initial costs of surgery and subsequent time-consuming maintenance procedures may be traded off by long-term gains in quality of life (HrQoL) compared to conventional medication treatment. This leads to the question whether DBS is cost effective compared to best medical treatment. METHODS: We present a lifetime Markov model for Parkinson's disease, comparing deep brain stimulation vs. best medical treatment and estimating the impact on health-related quality of life. HrQoL was measured by the EQ-5D and cost from the societal perspective of Germany. Both were discounted with 3% p.a.. Data on DBS efficacy and adverse events were taken from clinical studies and published reports or meta-analyses. Key assumptions on the surgery procedure and its durability, its impact on cost and HrQoL, mortality, prevalence of motor complications as well as stage transition probabilities and the discount rate were investigated by one-and two-way sensitivity analyses. RESULTS: The incremental cost effectiveness ratio (ICER) for DBS was a42,183 per QALY gained. Incremental DBS costs were due to cost for surgery and subsequent battery change. HrQoL was improved and motor complications were reduced. The following variables had most impact in sensitivity analyses: utility improvement under DBS, drug and surgery cost, progression rates, and discount rate leading to varying ICERs between 20,064 and a58,147/QALY (the latter due to extreme and unlikely parameter combinations). CONCLUSIONS: Based on our decision analysis using current guidelines, DBS is likely to be costeffective compared with other well-accepted health care technologies. We suggest to adopt DBS for patients with high drug cost or severe motor complications.
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COST-EFFECTIVENESS OF A NEW ABSORBABLE HYDROGEL FOR THE PREVENTION OF CSF LEAKS IN FRENCH HOSPITALS
Castanier JC 1 , Maunoury F 2 , Hédoux S 3 , Auffrand M 3 1 Independent Consultant in Health Economics, Lyon, France, 2 STATESIA, Le Mans, France, 3 FRAVIMED, Lyon, France OBJECTIVES: The objective was to demonstrate the cost-effectiveness of a new absorbable hydrogel used in craniotomies compared to the option "do nothing" in France. METHODS: A Markov model was fed with clinical data from Grotenhuis and al. (Surg. Neurol. 2005 ;64:490-3) and with cost data from the French cost database (2006 data based on DRG (GHM) 01C04V craniotomy without complication and 01C04W craniotomy with complication). The model was run with three stages (T0: date of surgery; T1: 1-month follow-up; T2: 3-month follow-up) and three states (no CSF leak; CSF leak; death). The effectiveness outcome measure was a utility index given to each state based on the hypothesis that utility was 1 for "no CSF leak"; 0.5 for "CSF leak" and 0 for "death". RESULTS: When hydrogel was used, the probabilities were for no CSF leak 1.000 at T0; 0.936 at T1 and 0.876 at T2; for CSF leak 0.000 at T0; 0.043 at T1 and 0.082 at T2; and for death 0.000 at T0; 0.021 at T1 and 0.042 at T2. When no hydrogel was used, the probabilities were for no CSF leak 0.060 at T0; 0.876 at T1; 0.767 at T2; for CSF leak 0.940 at T0; 0.103 at T1 and 0.191 at T2; and for death 0.000 at T0; 0.021 at T1 and 0.042 at T2. The costeffectiveness ratio was a4,720.20 at T0; a5,174.29 at T1 and a5,645.06 at T2 when hydrogel was used and it was a27,693.48 at T0; a14,251.71 at T1 and a12,638.00 at T2 when hydrogel was not used. The ICER, which represents the additional cost necessary to gain one additional utility unit, was a9857.12. CONCLUSIONS: The strategy with hydrogel was more cost-effective than the strategy without hydrogel. (SGX) is a modified -cyclodextrin that has been recently marketed in Spain for the reversal of neuromuscular block induced by rocuronium (ROC) and vecuronium. The objective of this study was to evaluate the costeffectiveness of sugammadex in the management of patients with unanticipated difficult intubation and patients needing rapid sequence intubation from the Spanish National Health System perspective. METHODS: Two decision-analytic models were developed to assess the average per patient treatment costs (a2009), life-years gained, and incremental cost per life-year gained of ROC SGX vs. succinylcholine in patients needing rapid sequence intubation and ROC SGX vs. all other neuromuscular blocking agents in the management of the unanticipated difficult intubation patients. The models simulate the probability of not being able to intubate, the probability of experiencing an adverse effect, and the direct costs produced by each treatment alternative. Clinical data was obtained from the SmPC of each drug and form secondary sources. Costs were obtained for Soikos database. All data was validated by a focus group in order to adapt the model to the Spanish clinical practice. RESULTS: In the management of unanticipated difficult intubation patients, ROC SGX is associated with higher life years gained and less costs than the intubation with atracurium or cisatracurium and with a mean cost per life year gained (LYG) of a11,077 vs. succinylcholine based regimens. In the rapid sequence intubation model, ROC SGX is associated with mean expected costs of a58.11 and mean expected life years of 20.38, and succinylcholine with a57.89 and 20,37, meaning a cost per LYG of ROC SGX vs succinylcholine of a3106. CONCLUSIONS: Under the established assumptions, sugammadex would be a cost-effective alternative for the reversal of patients with unanticipated difficult intubation or for the management of patients undergoing rapid sequence intubation.
PND19
COST-EFFECTIVENESS OF SUGAMMADEX IN THE MANAGEMENT OF PATIENTS WITH UNANTICIPATED DIFFICULT INTUBATION AND PATIENTS NEEDING RAPID SEQUENCE INTUBATION
PND20
REVERSAL OF NEUROMUSCULAR BLOCKADE WITH SUGAMMADEX-COST-EFFECTIVENESS ANALYSIS
Calado F 1 , Félix J 2 , Rabiais S 1 , Vilela H 3 1 Exigo Consultores, Alhos Vedros, Portugal, 2 Exigo Consultores, Alhos Vedros, Lisbon, Portugal, 3 Hospital Fernando Fonseca, Amadora, Portugal OBJECTIVES: To assess the cost-effectiveness of sugammadex for reversal of neuromuscular blockade (NMB) in Portuguese hospitals, using a clinical decision model. METHODS: We compared sugammadex 2.0 mg/kg with neostigmine 50 g/kg plus atropine 0.375 mg. Clinical efficacy and safety data were obtained from both published literature and phase III randomized clinical trial supporting the need for routine reversal of rocuronium or vecuronium NMB. Clinical events considered were drug adverse reactions and post-operative residual curarization. Risk of death within hospitalization, duration and cost of hospitalization were estimated from hospitalizations in Portuguese public hospitals during 2007, with at least one surgical procedure. Only direct costs were considered (drugs, medical visits, side effect treatments and monitoring). Effectiveness was measured in life years (LY). Premature death accounted to LY as the loss of remaining lifespan. Monte Carlo simulations were used to assess secondorder uncertainty. RESULTS: NMB reversal with sugammadex was estimated to result in a per patient gain of 2.25 LY (95%CI [1.78; 2.74]) and a decrease of a1509 (95%CI [-6,148 ; 738]) on total cost when compared to the neostigmine-atropine alternative, being on average a dominant strategy. Probabilistic sensitivity analysis revealed 82.6% probability of sugammadex dominance and 100% of being cost-effective at a threshold of a1000. CONCLUSIONS: Neuromuscular blockade reversal with sugammadex may be considered a cost-effective strategy in comparison to neostigmine-atropine.
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COST-EFFECTIVENESS OF RASAGILINE COMPARED TO OTHER FIRST LINE TREATMENT OPTIONS OF EARLY PARKINSON'S DISEASE IN THE UNITED STATES
Farkouh R 1 , Wilson MR 1 , Tarrants ML 2 , Castelli-Haley J 2 , Armand C 3 1 RTI Health Solutions, Research Triangle Park, NC, USA, 2 Teva Neuroscience, Kansas City, MO, USA, 3 H. Lundbeck A/S, Paris, France OBJECTIVES: We examined whether rasagiline, a once-daily irreversible monoamine oxidase type-B inhibitor indicated for treatment of early Parkinson's disease, is a cost-effective first-line treatment strategy when compared with ropinirole XL, pramipexole, generic ropinirole, and first-line levodopa. METHODS: We developed a 5-year Markov model to examine the cost-effectiveness of initiating early treatment of PD with rasagiline from a United States payer perspective. Comparator strategies included initiating therapy with ropinirole XL, pramipexole, generic ropinirole, or levodopa. Rasagiline was followed by either a dopamine agonist (DA) or levodopa. DA was followed by levodopa. Patients on a DA or levodopa could develop dyskinesias. Health state transitions occurred every 6 months. Transition probabilities were from clinical trial data. Drug costs, medical costs and utility weights were from published sources. One-way and probabilistic sensitivity analyses were performed. Costs and outcomes were discounted at 3% per year. RESULTS: Over 5 years, first-line treatment with rasagiline was cost saving and more effective when compared to branded DAs and levodopa. Rasagiline was cost-effective versus generic ropinirole at $1,838 per qualityadjusted life-year (QALY): incremental costs $239 and incremental QALYs 0.13. After five years compared to a DA, 23% and 50% fewer patients who initiated treatment with rasagiline were taking levodopa and experiencing dyskinesias respectively. Compared to first-line levodopa, 52% and 69% fewer patients starting rasagiline were taking levodopa and experiencing dyskinesias respectively. CONCLUSIONS: Initiating early Parkinson's disease therapy with rasagiline delayed treatment with levodopa, reduced dyskinesias, and appears to be cost-savings or cost-effective when compared to initiating therapy with other first-line therapies.
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COST-EFFECTIVENESS OF DONEPEZIL IN ALZHEIMER'S DISEASE IN SWEDEN
Mesterton J 1 , By Å 2 , Sandelin R 2 , Jönsson L 1 1 i3 Innovus, Stockholm, Sweden, 2 Pfizer AB, Sollentuna, Sweden OBJECTIVES: The societal costs of caring for patients with Alzheimer's disease (AD) are substantial. In light of increasing AD prevalence, there is a need for efficient allocation of available resources and despite few therapeutic alternatives the costeffectiveness of treatment with cholinesterase inhibitors has been the issue of much debate. The objective of this study was to use recently collected data on costs and utilities at different stages of AD to estimate the cost-effectiveness of donepezil compared to placebo in mild-to-moderate AD in Sweden. METHODS: A twelve state Markov-model was developed, incorporating cognitive function (mild/moderate/ severe), ADL-dependency (independent/dependent) and care setting (home/institution). Data on efficacy and disease progression were based on a 1-year clinical trial in Northern Europe and costs and utilities were based on a recently conducted cost-ofillness study in Sweden. The cohort was simulated over five years in 6-month cycles. Patients were assumed to receive treatment during one year, and after that disease progression rates were assumed to be identical in the donepezil and the placebo group. RESULTS: In base case scenario, the treatment cost of donepezil (11,023 SEK) was offset by lower other costs of care (17,618 SEK), resulting in an overall cost-saving of 6595 SEK per patient compared to placebo. Donepezil treatment also delayed progression into severe AD, ADL-dependence and institutionalization and led to a gain of 0.056 quality-adjusted life-years (QALY). Sensitivity analyses were carried to analyze the impact of extending the period under which treatment costs were incurred and by altering the baseline characteristics. Donepezil was cost-saving in most of these alternative scenarios and cost-effective in all of them. CONCLUSIONS: Using new data on costs and utilities in AD, donepezil treatment in mild-to-moderate AD is cost-saving compared to placebo. Treatment delays progression into severe AD, ADLdependence and institutionalization and thereby leads to QALY gains.
PND23 HEALTH ECONOMIC EVALUATION OF LAMOTRIGINE VERSUS LEVETIRACETAME IN THE INITIAL MONOTHERAPY OF EPILEPSY (LALIMO-TRIAL)
Balzer-Geldsetzer M, Reese JP, Rosenow F, Strzelczyk A, Hamer HM, Dodel R Philipps University, Marburg, Germany OBJECTIVES: Health economic evaluation on the relative value of lamotrigine (LTG) and levetiracetame (LEV) in the initial monotherapy of epilepsy METHODS: Paralleling an open label, prospective, randomised, multicenter trial including 409 epilepsy patients, a health economic evaluation of 81 participants aged 18 years was conducted. Data collection was done by the CRF of the clinical trial and in a series of three telephone interviews (baseline and two follow up calls, 3 and 6 months after baseline, respectively). The telephone interviews comprised sociodemographics, as well as instruments for the evaluation of health-related quality of life, depression and resource use). RESULTS: Eighty-one epilepsy patients were included in the economic evaluation. Thirty-eight (46.9%) patients were female: 21 (53.8%) in the LTG arm and 17 (40.5%) in the LEV arm. The mean duration of the disease was 2.0 3.9 years (LTG) and 2.2 6.1 years (LEV). Over the survey period, there was no significant difference concerning the number of ambulatory consultations (LTG 28 vs. LEV 26) or stationary hospital care (LTG 33 vs. LEV 38), though there was a trend for more
